October 2024: The TGA approved an alternative to the permethrin 5% w/w cream product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until March 31, 2025 (unless lapsed on an earlier date). Contact Us for more details.

​

September 2024: TGA approved the importation of an alternative to Ezetimibe 10 mg tablets currently in shortage until 31 March 2025 (unless lapsed on an earlier date). Contact Us for more details.

​

September 2024: The TGA approved the importation of an alternative to tadalafil 5 mg tablets under S19A of the Therapeutic Goods Act, 1989 until 30th of November 2024 (unless lapsed on an earlier date). Contact Us for more details.

​

September 2024: Fosaprepitant for injection is now available from all wholesalers. Contact Us for more details

 

August 2024: The TGA approved the importation of an alternative to 0.9% Sodium Chloride solution for infusion in COSINUS bag 1000mL (Carelide, France) under S19A of the Therapeutic Goods Act, 1989 until April 30, 2025 (unless lapsed on an earlier date). Contact Us for more details.

​

June 2024: The TGA approved the importation of an alternative to povidone iodine solution under S19A of the Therapeutic Goods Act, 1989 until November 30, 2024 (unless lapsed on an earlier date). Contact Us for more details.

​

June 2024: The TGA approved the importation of an alternative to cefuroxime 125mg/5 mL granules for oral suspension under S19A of the Therapeutic Goods Act, 1989 until June 30, 2025 (unless lapsed on an earlier date). Contact Us for more details.

 

May 2024: The TGA approved an alternative to the permethrin 5% w/w cream product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until October 31, 2024 (unless lapsed on an earlier date). Contact Us for more details.

​

April 2024: The TGA approved an alternative to the XYLOCAINE 2% with Epinephrine 1:200,000 20ml ampoule product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until September 30, 2024 (unless lapsed on an earlier date). Contact Us for more details.

​

April 2024: The TGA approved an alternative to the 25 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until October 31, 2024 (unless lapsed on an earlier date). Contact Us for more details.

​

April 2024: NELARABINE-REACH is now approved in Australia and is available at all wholesalers. Contact Us for more

details.​